News Release

HYDERABAD, INDIA (13 May 2025) - Suven Life Sciences Limited ("Suven") today announced audited financial results for the quarter and year ended 31 March 2025. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13 May 2025 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, ecept EPS

	Quarter ended			Year ended	
	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
Revenue	*26.90*	*32.40*	*66.68*	*175.53*	*328.23*
R&D and Operational expenses	452.88	408.16	326.73	1,724.29	1,396.98
Depreciation and Amortisation	13.47	15.34	15.08	58.22	65.02
Finance cost	-	0.08	0.30	0.47	1.58
Total expenses	*466.34*	*423.57*	*342.11*	*1,782.98*	*1,463.58*
Exceptional items (insurance claim received)	-	-	-	-	74.57
Tax	-	-	(10.02)	-	(10.02)
Profit/(Loss) After Tax for the period/year	*(439.45)*	*(391.17)*	*(265.41)*	*(1,607.45)*	*(1,050.76)*
Other comprehensive income	(5.70)	(0.05)	(2.02)	(5.83)	(0.60)
Total comprehensive income	*(445.15)*	*(391.21)*	*(267.43)*	*(1,613.28)*	*(1,051.36)*
Paid up equity capital	218.07	218.07	218.07	218.07	218.07
Earnings per share of Rs.1 each (EPS)	*(2.02)*	*(1.79)*	*(1.22)*	*(7.37)*	*(4.82)*

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer's type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of FY26.
- SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy in Q2-FY26.
- SUVN-911 (Ropanicant) – Phase 2A open label study for Major Depressive Disorder in USA successfully completed. Initiated Phase 2B clinical study in Q1-FY26.
- SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during FY26.
- SUVN-I6107 – Phase 1 study initiated during FY25 is continuing for establishing safety and pharmacokinetics of the molecule.

(d) Board of Directors of Suven approved fund raising of INR 8,576.40 million through fully convertible warrants on preferential basis to continue the funding of R&D, Clinical Development programs and general corporate purposes and CAPEX for creating new R&D facility. More information will be provided in the notice to the EGM proposed.

(e) Suven continues its R&D programs focused on Central Nervous System (CNS) disease disorders and granted 20 patents during the period covering countries Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa and USA.

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.